CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 54 enrolled
Drug / intervention
Zostavax™biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01911065
NCT01911065Phase 4Completed
CompareCT.gov

T Cell Responses to Varicella Zoster Virus After Vaccination and Viral Escape

Stanford University·interventional·Posted Jul 30, 2013·Updated Dec 18, 2023

In Brief

A Phase 4 clinical trial evaluating Zostavax™ for Herpes Zoster. Completed, enrolled 54 participants across 1 site.

Detailed Summary

In this study the investigators are trying to identify immune signatures that are associated with effective or poor vaccine responses to naturally-acquired herpes zoster virus and the zoster (shingles) vaccine, Zostavax.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 30, 2013
Enrollment StartSep 1, 2010
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.9 years ago

Interventions

Zostavax™biological

In the Vaccination arm, healthy individuals will be vaccinated with the licensed zoster vaccine, Zostavax.